| TUMOR MUTATIONAL BURDEN AS A BIOMARKER OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS
Tumor mutational burden (TMB) is the total number of somatic mutations in a defined region of a tumor genome and varies according to tumor type as well as among patients. [1] [2] [3] [4] For some tumors, particularly those with high TMB, such as melanoma and lung cancers, evidence is emerging for the association of TMB with neoantigen load. [2] [3] [4] [5] Neoantigens are novel tumor cell surface epitopes, some of which can be recognized as foreign to the body by the immune system, resulting in increased T-cell reactivity and thereby leading to an antitumor immune response ( Figure 1 ). 1, 4, [6] [7] [8] [9] Immune checkpoint inhibitors enhance antitumor T-cell activity via inhibition of immune checkpoint molecules, such as programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and cytotoxic T lymphocyte antigen-4
(CTLA-4), which negatively regulate T-cell activation and contribute to tumor immune response evasion. [10] [11] [12] Therefore, for some tumor types, neoantigen load or TMB may be a suitable clinical biomarker to guide treatment decisions for immune checkpoint inhibitors. While not all mutations result in immunogenic neoantigens and determining which mutations are likely to induce immunogenic neoantigens remains a challenge, TMB represents a quantifiable measure of the number of mutations in a tumor that can be used to inform treatment selection. 4 Clinical data demonstrating that patients with tumors that have high neoantigen load or high TMB are more likely to achieve clinical benefit from treatment with immune checkpoint inhibitors are accumulating. 1, [13] [14] [15] Investigation of TMB as a biomarker of response to immune checkpoint inhibitors has increased over recent years. These studies have identified an association between elevated TMB and improved patient outcomes in response to anti-PD-1/PD-L1 and anti-CTLA-4 therapies in multiple tumor types. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Most studies to date have investigated the association of patient outcomes and TMB in patients with non-small cell lung cancer (NSCLC). Other studies have assessed this association in patients with melanoma, squamous cell carcinoma of the head and neck, small cell lung cancer, and urothelial carcinoma.
Data from retrospective or exploratory analyses indicate that TMB may be an independent biomarker for clinical efficacy of PD-1/PD-L1
and CTLA-4 inhibitors. [16] [17] [18] [19] [20] 24, [26] [27] [28] [29] These observations were recently corroborated in clinical studies in patients with NSCLC treated with nivolumab in combination with ipilimumab and with atezolizumab, where high TMB (defined as ≥10 mutations per megabase [mut/Mb] and ≥14 mut/Mb, respectively) was prospectively assessed as clinically predictive for increased progression-free survival. 21, 23 The escalation of published studies in 2017 and 2018 compared with previous years demonstrates the increased awareness of assessing TMB as a predictive marker for response to immune checkpoint inhibitors, a trend that is set to continue.
| THE FUTURE CLINICAL LANDSCAPE OF TMB
Alongside data from published studies demonstrating the association of TMB and response to immune checkpoint inhibitors, additional ongoing and planned clinical trials with a key TMB component in their design are emerging. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 30 A search of the United States-focused ClinicalTrials.gov database (search terms "tumor mutation burden", "tumor mutational burden", "tumor mutation load", "tumor mutational load" [performed July 26, 2018] [33] [34] [35] [36] Although not yet approved for such use in the clinical setting, these assays can be used for TMB assessment. Furthermore, several targeted gene panel assays are currently being developed and validated by diagnostic companies and academic institutes, including some specific for TMB assessment in blood.
The increase in TMB assessment by various methods has brought with it a confusing array of information that documents how TMB has been determined and reported. The wide variation in TMB estimation and reporting methods across studies that have already been published demonstrates an evident lack of standardization and harmonization of current TMB assessment methods (Table 1) . [16] [17] [18] [19] [20] [21] [22] [23] [24] [26] [27] [28] [29] [37] [38] [39] These extensive differences may arise from the theoretic framework, technical methods applied, and the way that TMB data are reported, and will be described in more detail in the later sections of this article.
Together, the increased interest in using TMB to select patients who will most likely benefit from immune checkpoint inhibitors, Together, data from these multidisciplinary TMB standardization and harmonization approaches cover a wide spectrum of critical aspects of TMB assessment to propose recommendations for consistent TMB estimation, assay comparability, and TMB cutoff values for potential clinical use. 43 
| VARIATION IN TMB ASSESSMENT AND FACTORS THAT IMPACT TMB OUTPUT
Review of the published literature indicates that several factors influence TMB assessment, and results of preliminary analyses from the Friends and QuIP initiatives indicate that certain factors have greater impact than others on TMB estimation and reporting; as summarized in Figure 3 and Table 2 , and discussed below. and/or splicing profiles may differ from reference profiles, resulting in miscounts and impacting the TMB score reported. 47, 48 To date, most of the published studies have assessed TMB in solid tumor samples; however, blood TMB assessment assays are increasingly being used to assess TMB association with response to immune checkpoint inhibitors (Table 1) . Because TMB is most commonly assessed using FFPE tumor tissue samples, the initiative by Friends and QuIP proposes recommendations for standardized TMB assessment in these samples; however, TMB assessment using liquid samples is being evaluated by many other groups. Currently, there are several limitations to using other samples for TMB assessment, including that due to low levels of circulating tumor DNA (ctDNA), liquid samples may not yield sufficient quantity for NGS analysis. 24, [49] [50] [51] [52] [53] Reports show that the sensitivity and accuracy of TMB assay results from liquid samples depend on, among other factors, variability in tumor DNA in the blood. ctDNA can have heterogeneous origins and can be altered by treatment, thereby leading to variation in the final TMB score. 24, [49] [50] [51] [52] [53] Several ongoing studies are evaluating reliability of TMB assessment from blood samples and harmonizing tissue and blood-derived TMB, including use of the bTMB assay developed by Foundation Medicine. 20, 24, 53, 54 The potential limitations of specificity, sensitivity, and robustness of TMB assessment using blood samples should be further investigated and appropriate guidance should be given on how to address such limitations. Similarly, genome profiling in cytology samples requires a minimum level of cellularity and tumor content, and use for TMB assessment should be further investigated. 55 
FIGURE 3
Factors that impact TMB or TMB estimation and reporting throughout the TMB assessment process. Abbreviations: CNA, copy number alteration; FFPE, formalin-fixed, paraffin-embedded; indels, short insertions and deletions; QC, quality control; SNV, single nucleotide variant; TMB, tumor mutational burden; WES, whole exome sequencing 56, 57 Tumor purity Infiltration of tumor with immune or TME cells may impact TMB score (lower tumor purity is associated with reduced sensitivity) 32 Sequencing parameters Genomic region covered TMB score will depend on panel size and genomic region covered. Greater panel sizes are associated with more precise TMB estimated values 4, [62] [63] [64] [65] [66] [67] [68] [69] Genes included in panel Gene selection in panels is biased toward frequently mutated cancerassociated genes, and mutation patterns of these genes are often nonrandom. 33 TMB scores may depend on whether the panel contains specific genes that harbor frequent mutations in specific tumor types
Depth of coverage
Reduced depth of coverage is associated with reduced sensitivity 33, 61 Bioinformatics Germline variant removal/filtration Major germline genomic databases have different population race distribution and allele frequency spectrum of variants. TMB score will depend on selection of population allele frequency database when matched tumor-normal tissue is not available 4 Reference transcript source The choice of reference transcript source may impact TMB score depending on the variants considered and counted 48 Variants counted in TMB calculation Panels may consider all variant types or only some of them during their TMB calculations. 1,4,33 TMB score will depend on how comprehensive the variant counting rules are
Mutation callers
Mutation callers will count variants differently, with some being more comprehensive than others. 71 There is no optimal mutation caller, so a combination of different callers may be most optimal Allele frequency/fraction Reduced variant allele fraction is associated with reduced sensitivity 74 Minimum variant count Reduced variant counts are associated with reduced sensitivity 62 Cutoff variables Tumor type TMB differs widely across tumor types. The cutoff chosen must be appropriate for the tumor type being tested for a reliable and clinically meaningful TMB score to define high TMB [2] [3] [4] [5] Abbreviations: FFPE, formalin-fixed, paraffin-embedded; TMB, tumor mutational burden; TME, tumor microenvironment TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented. 32 Preanalytical factors can also have significant effects on TMB estimation, including those that apply to all genomic profiling assays, such as sample collection and processing, input material quality and quantity, sample fixation methodology, FFPE-induced deamination artefacts, and NGS library preparation. 56, 57 These factors affect the quantity and quality of DNA extracted for TMB assessment by either WES or targeted gene panel assays, and therefore, TMB estimation output. For example, low tumor purity, which can result from infiltration of immune or tumor microenvironment cells, can lead to reduced TMB assay sensitivity.
Also, fixation time is a preanalytical factor that influences the introduction of FFPE-induced deamination artefacts, which also impacts TMB estimation at the stage of bioinformatic analysis. 58, 59 For sequencing, genome coverage differs between WGS, WES, and targeted gene panel assays. WGS covers the whole genome, WES covers the entire exome coding region, and targeted gene panels cover specified areas that may or may not include tumor suppressor genes, driver genes, or intronic regions. 4, 60, 61 Moreover, the size and location of the capture region differs between targeted gene panel assays. It is important to carefully consider the panel size and composition for accurate TMB assessment. Supporting this concept, it has been observed that confidence intervals for TMB estimation increase with the use of gene panels that assess a smaller area of the genome compared with those that assess a larger area, which suggests that using smaller coverage gene panels could lead to the overestimation or underestimation of TMB. 4, [62] [63] [64] [65] [66] [67] [68] [69] Depth of sequencing also differs between WES and targeted gene panel assays; sequencing depth is greater for targeted gene panels (~500×) than for WES (~100×). 4, 61, 64 Genome coverage and sequencing depth together determine assay sensitivity and specificity, and therefore, influence TMB estimation output.
Bioinformatic algorithms can differ widely across targeted gene panels and although these factors heavily influence TMB estimation and reporting, the specifics are often not reported ( Table 1 ). The mutation types considered for TMB assessment can vary from one assay to another. These may include or exclude short insertions and deletions (indels) and/or synonymous and nonsynonymous base substitutions/single nucleotide variants. 4, 33, 70 For example, from retrospective analyses, it has been observed that TMB assessed by WES often includes missense mutations only, leaving out indels and other mutations, whereas some targeted panels include these variant types. 4, 18, 20, 21, 24, 26, 27 This is an important consideration due to the impact of indels and frameshift mutations on neoantigen formation. 4 However, calling indels can be challenging and their inclusion may depend on the sensitivity of the methods used to detect them. 71 Other bioinformatic parameters that impact TMB estimation and reporting include quality control metrics and various data-filtering procedures for inclusion/exclusion of a variant in the TMB estimation. 4, 18, 33, 38, 48 Filtering algorithms and cutoffs for putative germline variants, variant allele frequency (VAF), and FFPE-induced deamination artefacts vary between assays and can be affected by biological and preanalytical factors.
For example, VAF cutoffs can vary from 0.5 to 10%, with lower thresholds increasing the risk of including false-positives arising from contamination or sequencing artefacts. and reliability, and best practices for how to minimize and account for variability among assays (Table 3) . From results of preliminary analyses, we recommend that NGS assays provide as much patientrelevant genetic/molecular information as possible to avoid the need for rebiopsy and retesting of quality samples at baseline. This will be critical to guide immediate therapy selection with targeted therapies.
For example, testing of actionable driver mutations (eg, EGFR inhibitor therapies for EGFR-mutated lung cancers), genes associated with mutagenesis (eg, POLE), and potential negative predictors of response (eg, mutated β2M, JAK1/2, PTEN, STK11). [75] [76] [77] [78] We recommend that targeted gene panel assays that have larger genome coverage (ideally with~1 megabase being the lower limit) are used because they yield more reliable TMB estimation than smaller panels. [67] [68] [69] Of note, panels that cover less than 1 megabase are useful; however, accuracy may be reduced. [67] [68] [69] We also recommend the use of external reference sequence data, generated using agreed standard methodology such as WES, as this may enable and facilitate TMB assessment interpretability across panel assays.
Ongoing empirical and clinical analyses to generate reference standards, compare TMB measured by WES with TMB measured by various targeted gene panels, and evaluate and minimize interlaboratory and interassay variability are underway. These data will investigate additional aspects of TMB measurement to ensure consistency between assays and laboratories, based on the expectation that many laboratories may develop their own tests for TMB assessment. 
| CONCLUSIONS

